Literature summary for 3.4.21.68 extracted from

Cuadrado, E.; Ortega, L.; Hernandez-Guillamon, M.; Penalba, A.; Fernandez-Cadenas, I.; Rosell, A.; Montaner, J.
Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release (2008), J. Leukoc. Biol., 84, 207-214.

Search for more literature for 3.4.21.68

Application

Application	Comment	Organism
drug development	neutrophils are good candidates to be the main source of metalloproteinase-9 following t-PA stroke treatment and in consequence, are partially responsible for thrombolysis-related brain bleedings. Combined therapy of t-PA with a metalloproteinase-9 or a neutrophil degranulation inhibitor may improve safety and efficacy of thrombolytic therapy in the acute phase of stroke	synthetic construct

Organism

Organism	UniProt	Comment	Textmining
synthetic construct	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
additional information	t-PA treatment promotes metalloproteinase-9, metalloproteinase-8, and tissue inhibitor metalloproteinase-2 release from human neutrophils ex vivo within 10 and 30 min. t-PA treatment also promotes metalloproteinase-9 release in formyl peptide-preactivated neutrophils. t-PA treatment stimulates neutrophil degranulation	synthetic construct	?	-	?

Synonyms

Synonyms	Comment	Organism
t-PA	-	synthetic construct
Tissue plasminogen activator	-	synthetic construct

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)